Sign in to view content

Simultaneous Inhibition of Ang-2 and VEGF-A With Faricimab in DME: Additional Anatomical and Durability Outcomes From the BOULEVARD Phase 2 Trial

Vrinda S. Hershberger, MD, PhD

Video
Published 2019

Vrinda S. Hershberger, MD, PhD

Diabetic Retinopathy Part II Symposium

Related

What Is the Clinical Significance of Improving Diabetic Retinopathy for Vision Outcomes? A Meta-Analysis of 5 Ranibizumab Trials
Sophie Jane Bakri, MD
Annual Meeting Talks
2021
Systemic Adverse Events in Patients With Diabetes Treated With Intravitreal Antivascular Endothelial Growth Factor Injections
Roomasa Channa, MD
Annual Meeting Talks
2023
PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2025

Category: Diabetic Retinopathy

Diabetic Retinopathy

See more